FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068242558> ?p ?o ?g. }

• W2068242558 endingPage "407" @default.
• W2068242558 startingPage "404" @default.
• W2068242558 abstract "Controversy exists regarding optimal management of high risk localized endometrial cancer. Given that vaginal brachytherapy (VB) alone is used routinely at our institution, we retrospectively reviewed our outcomes among high risk patients defined according to the PORTEC, GOG 99, and/or Aalders randomized trials of pelvic radiation versus observation to determine if acceptable rates of locoregional control could be achieved with vaginal brachytherapy alone in this highest risk patient population.The Roswell Park Cancer Institute hospital tumor registry was used to identify all patients with Stage I or IIA endometrial cancer treated between January 1992 and June 2006. A total of 464 patients were identified. Of 261 patients who received post-operative RT, 225 received VB alone. Of those 225, 87 met the high risk criteria as designated by PORTEC (at least 2 of the following high risk features: age>60, Grade 3, and/or myometrial invasion >or=Occurrences of the mathematical operator' (='were changed to 'OE'. Please check.-->50%), GOG 99 (any age with 3 high risk features: Grade 2-3, >66% myometrial invasion, and/or LVSI; age >or=50 with 2 high risk features; or age >or=70 with 1 high risk feature), and/or Aalders (Stage IC, Grade 3). Descriptive recurrence statistics are provided.Among 87 high risk patients treated with VB alone, 36, 77, and 14 were high risk per PORTEC, GOG 99, and Aalders respectively. Forty (46%) underwent pelvic lymph node dissection. With a median follow-up of 52 months, 3 (3.4%) pelvic recurrences were observed including 1 vaginal recurrence, 1 pelvic recurrence, and 1 local recurrence involving both the vagina and pelvis. All 3 local recurrences were successfully salvaged with pelvic RT+/-surgery.This represents one of the largest known series of high risk localized endometrial cancer treated with VB alone. The observed 3.4% locoregional recurrence compares favorably with the 5% locoregional recurrence noted among the highest risk patients receiving pelvic RT in the PORTEC, GOG 99, and Aalders randomized trials. In this single institution experience, the 3 local recurrences were salvaged. Based on these findings, we will continue to use VB alone in the adjuvant setting for patients with high risk localized endometrial cancer." @default.
• W2068242558 created "2016-06-24" @default.
• W2068242558 creator A5006838625 @default.
• W2068242558 creator A5009400324 @default.
• W2068242558 creator A5021495689 @default.
• W2068242558 creator A5050714641 @default.
• W2068242558 creator A5056321055 @default.
• W2068242558 creator A5062355789 @default.
• W2068242558 creator A5074161282 @default.
• W2068242558 creator A5083223329 @default.
• W2068242558 date "2010-03-01" @default.
• W2068242558 modified "2023-10-12" @default.
• W2068242558 title "Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation" @default.
• W2068242558 cites W1973301611 @default.
• W2068242558 cites W1991935562 @default.
• W2068242558 cites W1994930432 @default.
• W2068242558 cites W2024578237 @default.
• W2068242558 cites W2031963846 @default.
• W2068242558 cites W2043103956 @default.
• W2068242558 cites W2054791534 @default.
• W2068242558 cites W2064600964 @default.
• W2068242558 cites W2071653457 @default.
• W2068242558 cites W2079856228 @default.
• W2068242558 cites W2092470911 @default.
• W2068242558 cites W2097409147 @default.
• W2068242558 cites W2103072200 @default.
• W2068242558 cites W2103408844 @default.
• W2068242558 cites W2127801054 @default.
• W2068242558 cites W2135987114 @default.
• W2068242558 cites W2147101451 @default.
• W2068242558 cites W2154098969 @default.
• W2068242558 cites W2263238851 @default.
• W2068242558 doi "https://doi.org/10.1016/j.ygyno.2009.06.027" @default.
• W2068242558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19944453" @default.
• W2068242558 hasPublicationYear "2010" @default.
• W2068242558 type Work @default.
• W2068242558 sameAs 2068242558 @default.
• W2068242558 citedByCount "35" @default.
• W2068242558 countsByYear W20682425582012 @default.
• W2068242558 countsByYear W20682425582014 @default.
• W2068242558 countsByYear W20682425582015 @default.
• W2068242558 countsByYear W20682425582016 @default.
• W2068242558 countsByYear W20682425582017 @default.
• W2068242558 countsByYear W20682425582018 @default.
• W2068242558 countsByYear W20682425582019 @default.
• W2068242558 countsByYear W20682425582021 @default.
• W2068242558 countsByYear W20682425582023 @default.
• W2068242558 crossrefType "journal-article" @default.
• W2068242558 hasAuthorship W2068242558A5006838625 @default.
• W2068242558 hasAuthorship W2068242558A5009400324 @default.
• W2068242558 hasAuthorship W2068242558A5021495689 @default.
• W2068242558 hasAuthorship W2068242558A5050714641 @default.
• W2068242558 hasAuthorship W2068242558A5056321055 @default.
• W2068242558 hasAuthorship W2068242558A5062355789 @default.
• W2068242558 hasAuthorship W2068242558A5074161282 @default.
• W2068242558 hasAuthorship W2068242558A5083223329 @default.
• W2068242558 hasConcept C121608353 @default.
• W2068242558 hasConcept C126322002 @default.
• W2068242558 hasConcept C141071460 @default.
• W2068242558 hasConcept C146357865 @default.
• W2068242558 hasConcept C151730666 @default.
• W2068242558 hasConcept C168563851 @default.
• W2068242558 hasConcept C2775862295 @default.
• W2068242558 hasConcept C2777088508 @default.
• W2068242558 hasConcept C2777416452 @default.
• W2068242558 hasConcept C2908647359 @default.
• W2068242558 hasConcept C29456083 @default.
• W2068242558 hasConcept C509974204 @default.
• W2068242558 hasConcept C71924100 @default.
• W2068242558 hasConcept C86803240 @default.
• W2068242558 hasConcept C99454951 @default.
• W2068242558 hasConceptScore W2068242558C121608353 @default.
• W2068242558 hasConceptScore W2068242558C126322002 @default.
• W2068242558 hasConceptScore W2068242558C141071460 @default.
• W2068242558 hasConceptScore W2068242558C146357865 @default.
• W2068242558 hasConceptScore W2068242558C151730666 @default.
• W2068242558 hasConceptScore W2068242558C168563851 @default.
• W2068242558 hasConceptScore W2068242558C2775862295 @default.
• W2068242558 hasConceptScore W2068242558C2777088508 @default.
• W2068242558 hasConceptScore W2068242558C2777416452 @default.
• W2068242558 hasConceptScore W2068242558C2908647359 @default.
• W2068242558 hasConceptScore W2068242558C29456083 @default.
• W2068242558 hasConceptScore W2068242558C509974204 @default.
• W2068242558 hasConceptScore W2068242558C71924100 @default.
• W2068242558 hasConceptScore W2068242558C86803240 @default.
• W2068242558 hasConceptScore W2068242558C99454951 @default.
• W2068242558 hasIssue "3" @default.
• W2068242558 hasLocation W20682425581 @default.
• W2068242558 hasLocation W20682425582 @default.
• W2068242558 hasOpenAccess W2068242558 @default.
• W2068242558 hasPrimaryLocation W20682425581 @default.
• W2068242558 hasRelatedWork W2016426829 @default.
• W2068242558 hasRelatedWork W2057864422 @default.
• W2068242558 hasRelatedWork W2380330452 @default.
• W2068242558 hasRelatedWork W2389281101 @default.
• W2068242558 hasRelatedWork W2407572472 @default.
• W2068242558 hasRelatedWork W2411709837 @default.
• W2068242558 hasRelatedWork W2413279076 @default.

• next